retatrutide trial results 2025 news 28.7% Weight Loss in New Study – Dr Brad Stanfield Lilly's Retatrutide Scores Triple Trial
Description
Tirzepatide is the first dual agonist which has been approved for chronic weight management, but numerous other dual and/or triple agonists (cagrisema, retatrutide, mazdutide and survodutide) are also in phase 3 trials as potential treatments for obesity and its metabolic complications
Both are simply the visible result of losing facial and body fat quickly
At LCS Medical Spa, we are dedicated to helping our clients achieve lasting wellness and aesthetic goals through personalized, evidence-based treatments
We collaborate closely with clients to create customized weight loss strategies that incorporate these elements, ensuring that medication is used safely and effectively
doi: 10.1371/journal.pntd.0005377
others require longer support depending on metabolic risk
